Results of a new study were recently released regarding Fasudil and CCMs in mice. Used in Japan, Fasudil is a drug used to treat brain aneurysm patients. While not currently approved for use in the United States, the genetically-modified mice treated with Fasudil in the study had fewer and smaller lesions than those who received the placebo.
From the Molecular Genetics and Microbiology Department (D.A. McDonald, D.A. Marchuk), Duke University Medical Center, Durham, NC; the University of Chicago Medical Center (C.S., R.S., F.L., I.A.A.), Biological Sciences Division, University of Chicago, Chicago, IL; and the Department of Medicine (R.A.S., M.H.G.), University of California, San Diego, San Diego, CA.
The Angioma Alliance blog posted recently about needing feedback and support regarding action groups. An excerpt:
Angioma Alliance helps us to set aside our differences to work together toward common goals: seeking a cure, finding peer support, answering research questions and helping each other to live full lives. The Board of Directors fully supports this solidarity and believes that we are stronger when we are together with our shared diagnosis of cavernous angiomas. However, we also think that there is a place for creating more specific groups, within the greater Angioma Alliance, for those who have particular concerns and interests. In this way, the organization can meet the needs of all our members in ways that serve each person best.
At this time, we are excited to see what groups may want to form and become what we are calling Action Group. As examples, the groups could focus on a particular problem, such as brainstem lesions, or a location, such as New Mexico.
It's an interesting post, and an even more interesting concept. I hope you check it out.